Fuji Yakuhin Co., Ltd.
18
0
0
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
22%
4 trials in Phase 3/4
0%
0 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Role: collaborator
Study of FFI-1010 in Pediatric Kidney Disease
Role: lead
Study of FYU-981 in Hyperuricemia With or Without Gout
Role: lead
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Role: lead
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Role: collaborator
Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)
Role: collaborator
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
Role: collaborator
Mass Balance Study of FYU-981
Role: lead
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
Role: lead
Clinical Pharmacology of FYU-981 (Final Formulation)
Role: collaborator
Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)
Role: lead
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
Role: collaborator
Study of FYU-981 in Hyperuricemia With or Without Gout
Role: lead
Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)
Role: lead
Single Dose Phase I Study of FYU-981
Role: lead
Repeated Dose Phase I Study of FYU-981
Role: lead
Clinical Pharmacology of FYU-981 (Elder Subjects)
Role: lead
Study of FYU-981 in Hyperuricemia With or Without Gout
Role: lead
All 18 trials loaded